NEW YORK (GenomeWeb News) — Illumina today said that an undisclosed top-5 US pharma company has bought a “multi-component genetic analysis system” and will use Illumina's Infinium assay and HumanHap650Y BeadChip to provide whole-genome genotyping in a project involving over 3,200 samples.
This configuration will enable the pharma to generate as many as 45 million genotypes per day and run gene-expression applications and automated sample and array processing, Illumina said.
Though the drug maker was undisclosed, a person close to the deal suggested it is likely either GlaxoSmithKline or Merck. Both companies have had recent relationships with San Diego-based Illumina, as reported by GenomeWeb News sister publication BioArray News.
Financial terms of the deal were not disclosed, though Illumina said this is a multi-million dollar deal. The company said it will issue details, including the name of the company, during its third-quarter conference call later today.